The real-world effectiveness of ocrelizumab for treating patients with MS: 1-year data from the MuSicalE study

被引：0
|
作者：
Trojano, M. [1 ]
Van Pesch, V. [2 ]
Al Roughani, R. [3 ]
Rovira, A. [4 ]
Cutter, G. [5 ]
Dzhenkova, D. [6 ]
Hagenbuch, N. [7 ]
Kantaria, R. [7 ]
Craveiro, L. [7 ]
Hobart, J. [8 ,9 ]
机构：
[1] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy
[2] UCLouvain, Clin Univ St Luc, Dept Neurol, Brussels, Belgium
[3] Amiri Hosp, Kuwait, Kuwait
[4] Univ Hosp Vall dHebron, Sect Neuroradiol, Barcelona, Spain
[5] UAB Sch Publ Hlth, Dept Biostat, Birmingham, AL USA
[6] F Hoffmann La Roche Ltd, Sofia, Bulgaria
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Plymouth Univ, Peninsula Sch Med, Plymouth, Devon, England
[9] Plymouth Univ, Peninsula Sch Dent, Plymouth, Devon, England
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-400
引用
收藏
页码：635 / 635
页数：1
相关论文
共 50 条
  • [1] ACAPELLA: real-world experience with ocrelizumab - an observational study evaluating safety in patients with relapsing and progressive MS, year four data
    Douglas, E.
    Jungquist, R. -M.
    Bouley, A.
    Katz, J.
    Lathi, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 656 - 657
  • [2] A real-world study of PIRA among MS patients treated with Ocrelizumab and Alemtuzumab
    Polidoro, Federica
    Zito, Antonio
    Singh-Curry, Victoria
    Nandoskar, Ashwini
    Felongco-sagge, Teresa
    Dela Cruz, Dionisio Johnny
    Dorsey, Rachel
    Muraro, Paolo
    Nicholas, Richard
    Scalfari, Antonio
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 369 - 370
  • [3] Ocrelizumab and hypogammaglobulinemia: a real-world retrospective MS cohort study
    Nobile, S.
    Beauchemin, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 324 - 324
  • [4] Safety and effectiveness of ocrelizumab in multiple sclerosis: a real-world study from spain
    Sempere, A.
    Berenguer-Ruiz, L.
    Burgos-San Jose, A.
    Aragones, M.
    Navarro-Lopez, M. D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 553 - 553
  • [5] Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study
    Gulliver, W.
    Alavi, A.
    Wiseman, M. C.
    Gooderham, M. J.
    Rao, J.
    Alam, M. S.
    Papp, K. A.
    Desjardins, O.
    Jean, C.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (12) : 2431 - 2439
  • [6] ACAPELLA: Real-World Experience with Ocrelizumab, 6-Year Data
    Douglas, Elizabeth
    O'Shea, Isabella
    Greenawalt, Paige
    Bouley, Andrew
    Lathi, Ellen
    Katz, Joshua
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 979 - 980
  • [7] Acapella: real-world experience with ocrelizumab: an observational study evaluating safety in patients with relapsing and progressive ms, year three
    Geils, H.
    Stribling, I.
    Katz, J.
    Lathi, E.
    Douglas, E.
    Bouley, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 256 - 256
  • [8] The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
    Ramos, Rosa
    Chazot, Charles
    Ferreira, Anibal
    Di Benedetto, Attilio
    Gurevich, Konstantin
    Feuersenger, Astrid
    Wolf, Melanie
    Arens, Hans-Juergen
    Walpen, Sebastian
    Stuard, Stefano
    [J]. BMC NEPHROLOGY, 2020, 21 (01)
  • [9] The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
    Rosa Ramos
    Charles Chazot
    Anibal Ferreira
    Attilio Di Benedetto
    Konstantin Gurevich
    Astrid Feuersenger
    Melanie Wolf
    Hans-Jürgen Arens
    Sebastian Walpen
    Stefano Stuard
    [J]. BMC Nephrology, 21
  • [10] REAL-WORLD CHARACTERIZATION OF HYPERTENSION PATIENTS IN JAPAN: A 1-YEAR OVERVIEW
    Crawford, B.
    Ong, S. H.
    Falvey, H.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A607 - A607
12345